Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

NCT05802225 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05802225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05802225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 30, 2023
Completion date
February 20, 2026
Enrollment
398 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer